---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-057577"
form_type: "8-K"
ticker: "CBDY"
cik: "0001586554"
company_name: "Target Group Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:24:52.143013+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Target Group subsidiary receives CDN$2.04M payout from Thrive, JV continues

## Summary
- CanaryRx (Target Group subsidiary) received CDN$2,043,082.74 from Thrive to fully repay JV indebtedness.
- Thrive paid the amount on May 6, 2022, satisfying all Outstanding JV and Product Obligations.
- The Joint Venture Operations Agreement between CanaryRx, Thrive, and JVCo remains in full force.
- The payout covers start-up hard costs ($921,581.48) and excess costs ($1,121,501.26).
- The agreement facilitates Thrive's parent Terrafarma's planned amalgamation with Aurora Cannabis Inc.

## SEC filing metadata
- accession: 0001104659-22-057577
- form_type: 8-K
- ticker: CBDY
- cik: 0001586554
- company_name: Target Group Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1586554/000110465922057577/0001104659-22-057577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1586554/000110465922057577/tm2214947d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-057577
- JSON: https://secwatch.observer/filing/0001104659-22-057577.json
- Plain text: https://secwatch.observer/filing/0001104659-22-057577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.